Complete Metabolic Response Assessed by FDG PET/CT to Paclitaxel-Ramucirumab in Patients With Metastatic Gastroesophageal Junction Cancer.

AbstractPaclitaxel-ramucirumab chemotherapy is indicated in second line of metastatic gastroesophageal junction cancer (mGEJC) after progression under platinum–5-FU chemotherapy. Nevertheless, the reported common response after treatment is only partial within series. To date, only 1 case report of